BRIEF published on 07/30/2026 at 16:27, 1 month 12 days ago The Vanguard Group Announces Position in Schroders PLC Form 8.3 Takeover Code Securities Disclosure Schroders Plc Vanguard Group
PRESS RELEASE published on 07/30/2026 at 16:27, 1 month 12 days ago Form 8.3 - The Vanguard Group, Inc.: Prologis Inc The Vanguard Group, Inc. discloses 13.58% interest in Prologis Inc. with 126,688,399 relevant securities. Additional disclosure for SEGRO plc Relevant Securities The Vanguard Group Inc. Interest Disclosure SEGRO PLC Prologis Inc.
PRESS RELEASE published on 07/30/2026 at 16:26, 1 month 12 days ago Form 8.3 - The Vanguard Group, Inc.: Rotork PLC The Vanguard Group, Inc. discloses 5.44% stake in Rotork PLC as of 29 July 2026 Vanguard Group Financial Disclosure Shareholding Stake Disclosure Rotork Plc
BRIEF published on 07/30/2026 at 16:25, 1 month 12 days ago The Vanguard Group Discloses Position in Segro PLC Form 8.3 Takeover Code Securities Disclosure Vanguard Group SEGRO PLC
PRESS RELEASE published on 07/30/2026 at 16:22, 1 month 12 days ago Form 8.3 - The Vanguard Group, Inc.: Schroders PLC The Vanguard Group, Inc. discloses 2.71% ownership in Schroders plc's 20p ordinary securities on 29th July 2026 The Vanguard Group Schroders Plc Ownership Disclosure 20p Ordinary Securities 29th July 2026
PRESS RELEASE published on 07/30/2026 at 16:20, 1 month 12 days ago Form 8.3 - The Vanguard Group, Inc.: Segro PLC The Vanguard Group, Inc. discloses 5.64% stake in Segro PLC as per Form 8.3 filing. Dealings & positions detailed in the disclosure Form 8.3 Disclosure Vanguard Group Financial Holdings SEGRO PLC
BRIEF published on 07/30/2026 at 16:20, 1 month 12 days ago The Vanguard Group Discloses Stake in Spire Healthcare Group Form 8.3 Takeover Code Securities Disclosure Vanguard Group Spire Healthcare
BRIEF published on 07/30/2026 at 16:18, 1 month 12 days ago The Vanguard Group Discloses Position in Tate & Lyle Form 8.3 Takeover Code Vanguard Group Shareholding Disclosure Tate & Lyle
PRESS RELEASE published on 07/30/2026 at 16:15, 1 month 12 days ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group PLC The Vanguard Group, Inc. discloses a 3.55% stake in Spire Healthcare Group PLC. Purchase of 5,030 securities at 2.34 GBP per unit disclosed on July 29, 2026 Vanguard Group Inc. Spire Healthcare 3.55% 5,030 Securities 2.34 GBP
PRESS RELEASE published on 07/30/2026 at 16:13, 1 month 12 days ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle PLC The Vanguard Group, Inc. discloses a 4.75% ownership in Tate & Lyle PLC with 21,140,995 shares. Dealings include purchase of 7,080 shares at 5.54 GBP per unit The Vanguard Group Ownership Disclosure Financial Market Share Dealings Tate & Lyle Plc
Published on 09/12/2026 at 02:35, 4 hours 26 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 8 hours 1 minute ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 8 hours 56 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 9 hours 36 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 14 hours 1 minute ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 22:15, 8 hours 46 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 8 hours 50 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 11 hours 16 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 12 hours 45 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/10/2026 at 19:30, 1 day 11 hours ago Availability of the 2026 Interim Financial Report
